SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Vestman Amanda)
 

Search: WFRF:(Vestman Amanda) > Improved treatment ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Improved treatment of glioblastoma : changes in survival over two decades at a single regional Centre

Eriksson, Maria (author)
Umeå universitet,Onkologi
Kahari, Jenna (author)
Umeå universitet,Klinisk neurovetenskap
Vestman, Amanda (author)
Umeå universitet,Klinisk neurovetenskap
show more...
Hallmans, Mattias (author)
Umeå universitet,Onkologi
Johansson, Mikael (author)
Umeå universitet,Onkologi
Bergenheim, A. Tommy (author)
Umeå universitet,Klinisk neurovetenskap
Sandström, Maria (author)
Umeå universitet,Onkologi
show less...
 (creator_code:org_t)
Taylor & Francis Group, 2019
2019
English.
In: Acta Oncologica. - : Taylor & Francis Group. - 0284-186X .- 1651-226X. ; 58:3, s. 334-341
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background: Glioblastoma (GBM) is an aggressive brain tumor with a short overall survival (OS) in general. The treatment of GBM has evolved over the last decades and is today multimodal including surgical resection followed by radiochemotherapy and adjuvant chemotherapy for patients in good performance status. The aim of this study was to evaluate the development of treatment and the outcome for GBM patients at a single regional center.Patients and methods: Survival was studied for 571 patients in our region diagnosed with GBM between 1995 and 2015. Samples from 244 patients out of those treated 2005-2015 have been included in a tissue/blood bank and a clinical database has been set up with basic patient characteristics and details on surgery and non-surgical treatment.Results: The median OS for all patients from 1995 to 2015 was 9.3 months. There was a stepwise improvement from 6.9 to 10.3 months for patients diagnosed 1995-1996 and 2010-2015, respectively (p<.05). The 2-year survival for the same time periods improved from 7% to 18% (p<.01). After introduction of postoperative radiochemotherapy for patients in good performance status in 2005 an increased OS was noted and following implementation of intraoperative 5-aminolevulinic acid the number of tumor resection 95% did increase from 33% to 54% (p<.001). Positive prognostic factors for survival were young age, good performance status, absence of inflammatory disease, absence of diabetes or metabolic disease, tumor resection 95%, and completion of postoperative radiochemotherapy.Discussion: The results of this study are consistent with earlier results regarding survival and prognostic factors and confirm results from randomized controlled trials in a clinical setting. Despite the improvements made, the prognosis is still dismal and the need for further research on GBM treatment is great.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view